Camps J, Crisóstomo S, García-Granero M, Riezu-Boj J I, Civeira M P, Prieto J
Department of Internal Medicine, Clínica Universitaria, Universidad de Navarra, Pamplona, Spain.
Gut. 1993 Dec;34(12):1714-7. doi: 10.1136/gut.34.12.1714.
Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of interferon alfa. For the purposes of this study, response was defined as the return to normal of aminotransferase activities before the third month of treatment. Seventy per cent of the patients responded to treatment. Six variables were associated with an increased likelihood of response assessed by univariate analysis. With stepwise multiple regression analysis assessment, however, only three variables remained independently predictive of response: low gamma glutamyltransferase (gamma GT) activities (p < 0.001), absence of obesity (p = 0.005), and absence of cirrhosis (p = 0.01). The response rate in patients with gamma GT activities < 0.66 mu kat/l (n = 55) was 78% and 60% in patients with values > 0.66 mu kat/l (n = 45) (p = 0.048). Response was attained in 75% of non-obese patients (n = 80), compared with only 50% of obese patients (n = 20) (p = 0.03). Finally, 80% of patients without cirrhosis (n = 76) responded, while among those with cirrhosis (n = 24) the response rate was only 37% (p < 0.001). All 23 patients without cirrhosis, <40 years old, and with gamma GT activities <0.66 mu kat/l responded to treatment, while only 28.5% of 14 patients with cirrhosis, >40 years old, and with gamma GT activities >0.66 mu kat/l responded to interferon alfa (p<0.001). Those findings may be useful when evaluating interferon alfa trials and it is suggested that this treatment should be applied early in the course of chronic hepatitis C.
能够预测慢性丙型肝炎对干扰素α治疗反应的预处理变量尚未得到充分评估。在连续接受12个月干扰素α疗程治疗的100例患者中,对18个基线变量进行了评估。在本研究中,反应被定义为治疗第三个月前转氨酶活性恢复正常。70%的患者对治疗有反应。单因素分析评估显示,有6个变量与反应可能性增加相关。然而,通过逐步多元回归分析评估,只有3个变量仍然独立预测反应:低γ-谷氨酰转移酶(γ-GT)活性(p<0.001)、无肥胖(p = 0.005)和无肝硬化(p = 0.01)。γ-GT活性<0.66μkat/L的患者(n = 55)的反应率为78%,而γ-GT活性>0.66μkat/L的患者(n = 45)的反应率为60%(p = 0.048)。75%的非肥胖患者(n = 80)获得了反应,而肥胖患者(n = 20)中只有50%获得反应(p = 0.03)。最后,无肝硬化的患者(n = 76)中有80%有反应,而有肝硬化的患者(n = 24)中反应率仅为37%(p<0.001)。所有23例无肝硬化、年龄<40岁且γ-GT活性<0.66μkat/L的患者对治疗有反应,而14例有肝硬化、年龄>40岁且γ-GT活性>0.66μkat/L的患者中只有28.5%对干扰素α有反应(p<0.001)。这些发现可能在评估干扰素α试验时有用,并且建议在慢性丙型肝炎病程早期应用这种治疗。